219 related articles for article (PubMed ID: 27807709)
41. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up.
Kim SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Oct; 26(10):1472-1479. PubMed ID: 27457917
[TBL] [Abstract][Full Text] [Related]
42. Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection.
Ryu YJ; Cho JS; Yoon JH; Park MH
World J Surg Oncol; 2018 Oct; 16(1):205. PubMed ID: 30314503
[TBL] [Abstract][Full Text] [Related]
43. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
44. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
45. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
46. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
Baek SK; Jung KY; Kang SM; Kwon SY; Woo JS; Cho SH; Chung EJ
Thyroid; 2010 Feb; 20(2):147-52. PubMed ID: 19785522
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma.
Michels JJ; Jacques M; Henry-Amar M; Bardet S
Hum Pathol; 2007 Feb; 38(2):212-9. PubMed ID: 17097131
[TBL] [Abstract][Full Text] [Related]
48. The presence of cancerous nodules in lymph nodes is a novel indicator of distant metastasis and poor survival in patients with papillary thyroid carcinoma.
Chen L; Zhu Y; Zheng K; Zhang H; Guo H; Zhang L; Wu K; Kong L; Ruan W; Hu J; Zhang X; Chen X
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1035-1042. PubMed ID: 28204971
[TBL] [Abstract][Full Text] [Related]
49. [Multifocal papillary thyroid carcinoma: clinical analysis of 168 cases].
Lin YK; Sheng JM; Zhao WH; Wang WB; Yu XF; Teng LS; Ma ZM
Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(6):450-3. PubMed ID: 19595234
[TBL] [Abstract][Full Text] [Related]
50. The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma.
Su DH; Chang SH; Chang TC
Clin Endocrinol (Oxf); 2015 Feb; 82(2):286-94. PubMed ID: 24863061
[TBL] [Abstract][Full Text] [Related]
51. Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases.
O'Neill CJ; Coorough N; Lee JC; Clements J; Delbridge LW; Sippel R; Sywak MS; Chen H; Sidhu SB
ANZ J Surg; 2014 Apr; 84(4):240-4. PubMed ID: 23316684
[TBL] [Abstract][Full Text] [Related]
52. Papillary thyroid carcinoma tall cell variant.
Ghossein R; Livolsi VA
Thyroid; 2008 Nov; 18(11):1179-81. PubMed ID: 18925842
[TBL] [Abstract][Full Text] [Related]
53. A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study.
Lee JH; Chung YS; Lee YD
Head Neck; 2017 Apr; 39(4):767-771. PubMed ID: 28139038
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma.
Akaishi J; Sugino K; Kameyama K; Masaki C; Matsuzu K; Suzuki A; Uruno T; Ohkuwa K; Shibuya H; Kitagawa W; Nagahama M; Shimizu K; Ito K
World J Surg; 2015 Jul; 39(7):1728-35. PubMed ID: 25743484
[TBL] [Abstract][Full Text] [Related]
55. Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1-4 cm: Preliminary results.
Kim MJ; Lee MC; Lee GH; Choi HS; Cho SW; Kim SJ; Lee KE; Park YJ; Park DJ
Clin Endocrinol (Oxf); 2017 Jul; 87(1):80-86. PubMed ID: 28338234
[TBL] [Abstract][Full Text] [Related]
56. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.
Verburg FA; Mäder U; Luster M; Reiners C
Eur J Endocrinol; 2009 Apr; 160(4):619-24. PubMed ID: 19158232
[TBL] [Abstract][Full Text] [Related]
57. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.
Russo M; Malandrino P; Moleti M; Vermiglio F; Violi MA; Marturano I; Minaldi E; Vigneri R; Pellegriti G; Regalbuto C
J Endocrinol Invest; 2017 Nov; 40(11):1235-1241. PubMed ID: 28528434
[TBL] [Abstract][Full Text] [Related]
58. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors.
Machens A; Holzhausen HJ; Lautenschläger C; Dralle H
Langenbecks Arch Surg; 2004 Aug; 389(4):278-82. PubMed ID: 15164288
[TBL] [Abstract][Full Text] [Related]
59. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
[TBL] [Abstract][Full Text] [Related]
60. Impact of invasive extranodal extension on the prognosis of patients with papillary thyroid carcinoma.
Moritani S
Thyroid; 2014 Dec; 24(12):1779-83. PubMed ID: 25157399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
